Natural Products and Pharmacological Properties of Symbiotic Bacillota (Firmicutes) of Marine Macroalgae

The shift from the terrestrial to the marine environment to discover natural products has given rise to novel bioactive compounds, some of which have been approved for human medicine. However, the ocean, which makes up nearly three-quarters of the Earth's surface, contains macro- and microorganisms whose natural products are yet to be explored. Among these underexplored marine organisms are macroalgae and their symbiotic microbes, such as Bacillota, a phylum of mostly Gram-positive bacteria previously known as Firmicutes. Macroalgae-associated Bacillota often produce chemical compounds that protect them and their hosts from competitive and harmful rivals. Here, we summarised the natural products made by macroalgae-associated Bacillota and their pharmacological properties. We discovered that these Bacillota are efficient producers of novel biologically active molecules. However, only a few macroalgae had been investigated for chemical constituents of their Bacillota: nine brown, five red and one green algae. Thus, Bacillota, especially from the marine habitat, should be investigated for potential pharmaceutical leads. Moreover, additional diverse biological assays for the isolated molecules of macroalgae Bacillota should be implemented to expand their bioactivity profiles, as only antibacterial properties were tested for most compounds.

Ethnopharmacology, phytochemistry and a new chemotaxonomic marker in Oldenlandia affinis (Roem. & Schult.) DC. Rubiaceae

The proper documentation of ethnopharmacological application of widely used indigenous plants and their phytochemical analysis has positively impacted the drug discovery pipeline. Medicinal plants with potential commercial value and prospects for clinical application need to be properly identified and authenticated to avoid confusion, adulteration and substitution. Oldenlandia affinis (OA) has continued to attract scientific attention following the discovery of extremely stable cyclotides (circular peptides) that are not expressed in many investigated members of the contentious genus, Oldenlandia (synonym – Hedyotis); yet there is a lack of an elaborate review covering some broader aspects of its traditional uses, ethnopharmacology and phytochemistry of the species. More importantly, the age long but lingering confusion and taxonomic inconsistencies common to the Oldenlandia–Hedyotis debate could foster species mismatching, increase cases of misidentification, promote adulteration of OA and thereby limit its proper clinical application. Here, we aim to reveal the extent of indigenous use of and research on OA from 1960 till date, unveil knowledge gaps, document hitherto unknown traditional applications, ethnopharmacological uses, pharmacological properties, and reported phytochemical profile. In addition, to encourage proper selection and utilization of genuine crude drug, the chemotaxonomically important phytoconstituents of OA have been presented and the modern approach of chemophenetic study of OA proposed to resolve the lack of consensus in the taxonomy of OA as well as the morphologically and anatomically close members of the taxon. The abundant cyclotide expression in OA represents a new chemotaxonomic marker for its unambiguous identification, utilization and reproducibility of research findings on the species.